Abstract
PurposeThis work aims to study the generalizability of a pre-developed deep learning (DL) dose prediction model for volumetric modulated arc therapy (VMAT) for prostate cancer and to adapt the model, via transfer learning with minimal input data, to three different internal treatment planning styles and one external institution planning style. MethodsWe built the source model with planning data from 108 patients previously treated with VMAT for prostate cancer. For the transfer learning, we selected patient cases planned with three different styles, 14–29 cases per style, in the same institution and 20 cases treated in a different institution to adapt the source model to four target models in total. We compared the dose distributions predicted by the source model and the target models with the corresponding clinical plan dose used for patient treatments and quantified the improvement in the prediction quality for the target models over the source model using the Dice similarity coefficients (DSC) of 0% to 100% isodose volumes and the dose-volume-histogram (DVH) parameters of the planning target volume and the organs-at-risk. ResultsThe source model accurately predicts dose distributions for plans generated in the same source style, but performs sub-optimally for the three different internal and one external target styles, with the mean DSC ranging between 0.81–0.94 and 0.82–0.91 for the internal and the external styles, respectively. With transfer learning, the target model predictions improved the mean DSC to 0.88–0.95 and 0.92–0.96 for the internal and the external styles, respectively. Target model predictions significantly improved the accuracy of the DVH parameter predictions to within 1.6%. ConclusionWe demonstrated the problem of model generalizability for DL-based dose prediction and the feasibility of using transfer learning to solve this problem. With 14–29 cases per style, we successfully adapted the source model into several different practice styles. This indicates a realistic way forward to widespread clinical implementation of DL-based dose prediction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.